SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

C54 - Multiple Sclerosis Therapy: Disease-modifying Treatment II

Event Time: Sunday April 23, 2017 3:30 pm to 5:30 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s): Bruce Cree MD, PhD, MCR
Description: Disease-modifying treatments in MS are one of the most rapidly evolving areas of therapeutic intervention in neurology. As new treatments become available, the options for patients, and their prescribing physicians, increases. Many of the newer therapies have complex risk: benefit profiles and require specialized expertise for safe and effective administration. Faculty will focus on therapeutic strategies and risk mitigation of currently available disease-modifying therapies, discuss proper use of these drugs and risk assessment, and use specific examples to cover the most frequent issues arising from MS treatment strategies. This program complements C36: Multiple Sclerosis Therapy: Disease-modifying Treatment I and C116: Multiple Sclerosis Therapy: Symptom Management, but covers independent topics.
Completion Message: Participants should be familiar with the indications and risks associated with approved disease-modifying agents in multiple sclerosis, and be better able to identify the appropriate patient populations for the newer agents.
CME Credits: 2
Core Competencies: Medical Knowledge, Patient Care

Program Speakers - Tentative

Start/End Time Title Faculty
3:30 PM - 4:25 PM Risk Stratification and Mitigation Bruce Cree MD, PhD, MCR 
4:25 PM - 4:30 PM Questions and Answers Faculty 
4:30 PM - 5:25 PM Emerging Therapies in MS: Slowing Progressive MS, Remyelination, Neural Protection, Neural Repair Gavin Giovannoni MD 
5:25 PM - 5:30 PM Questions and Answers Faculty 


Speaker Disclosure
Bruce A. C. Cree, MD, PhD, MCR Bruce Cree has received consulting honoraria from AbbVie, Biogen, EMD Serono, Novartis and Shire..

Gavin Giovannoni, MD Dr. Giovannoni has received personal compensation for activities with AbbVie, Bayer HealthCare, Biogen, Canbex, FivePrime, Genzyme, GlaxoSmithKline, GW Pharma, Merck Serono, Novartis, Protein Discovery Laboratories, Roche, Synthon, Teva Neuroscience, UCB, and Vertex for honoraria. Dr. Giovannoni has received personal compensation from Elsevier in a co-chief editor capacity of MS and Related Disorders. Dr. Giovannoni has received research support from Biogen, Ironwood, Merck Serono, Merz, and Novartis.

Register Now

Related Courses

Saturday April 21, 2018

9:30 AM-11:30 AM
C11 Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN

Sunday April 22, 2018

7:00 AM-9:00 AM
C33 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
3:30 PM-5:30 PM
C57 Spanish: Update on MS Therapy Lilyana Amezcua MD

Tuesday April 24, 2018

7:00 AM-9:00 AM
C98 Multiple Sclerosis Overview I: Clinical Pearls John Corboy MD, FAAN
1:00 PM-3:00 PM
C108 Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
3:30 PM-5:30 PM
C122 Multiple Sclerosis Overview III: Basic and Translational Science Michael Racke MD

Wednesday April 25, 2018

7:00 AM-9:00 AM
C136 Multiple Sclerosis Therapy: Disease-modifying Treatment I David Jones MD
9:15 AM-11:30 AM
PL5 Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C147 Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
3:30 PM-5:30 PM
C162 Multiple Sclerosis Therapy: Symptom Management Jonathan Carter MD

Thursday April 26, 2018

7:00 AM-9:00 AM
C175 Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
1:00 PM-3:00 PM
N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis Eric Klawiter MD,
Ellen Mowry MD, FAAN

Friday April 27, 2018

1:00 PM-3:00 PM
C224 Neuromyelitis Optica Spectrum Disorders Dean Wingerchuk MD, FAAN


Forgot Password?